» Articles » PMID: 9255793

Binding Proteins Selected from Combinatorial Libraries of an Alpha-helical Bacterial Receptor Domain

Overview
Journal Nat Biotechnol
Specialty Biotechnology
Date 1997 Aug 1
PMID 9255793
Citations 181
Authors
Affiliations
Soon will be listed here.
Abstract

Small protein domains, capable of specific binding to different target proteins have been selected using combinatorial approaches. These binding proteins, called affibodies, were designed by randomization of 13 solvent-accessible surface residues of a stable alpha-helical bacterial receptor domain Z, derived from staphylococcal protein A. Repertoires of mutant Z domain genes were assembled and inserted into a phagemid vector adapted for monovalent phage display. Two libraries, each comprising approximately 4 x 10(7) transformants, were constructed using either an NN(G/T) or an alternative (C/A/G)NN degeneracy. Biopanning against the target proteins Taq DNA polymerase, human insulin, and a human apolipoprotein A-1 variant, showed that in all cases significant enrichments were obtained by the selection procedures. Selected clones were subsequently expressed in Escherichia coli and analyzed by SDS-PAGE, circular dichroism spectroscopy, and binding studies to their respective targets by biospecific interaction analysis. The affibodies have a secondary structure similar to the native Z domain and have micromolar dissociation constants (KD) for their respective targets.

Citing Articles

Self-assembled proteomimetic (SAP) with antibody-like binding from short PNA-peptide conjugates.

Brennecke B, Civili B, Sabale P, Barluenga S, Meyer B, Winssinger N Proc Natl Acad Sci U S A. 2025; 122(7):e2412850122.

PMID: 39951509 PMC: 11848287. DOI: 10.1073/pnas.2412850122.


Surface Functionalization of Nanocarriers with Anti-EGFR Ligands for Cancer Active Targeting.

Spada A, Gerber-Lemaire S Nanomaterials (Basel). 2025; 15(3).

PMID: 39940134 PMC: 11820047. DOI: 10.3390/nano15030158.


Covalent Affibody-Molecular Glue Drug Conjugate Nanoagent for Proximity-Enabled Reactive Therapeutics.

Gao W, Yang X, Li Q, Liu Y, Huang W, Xia X Adv Sci (Weinh). 2025; 12(10):e2412273.

PMID: 39821590 PMC: 11905048. DOI: 10.1002/advs.202412273.


Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics.

Ou L, Setegne M, Elliot J, Shen F, Dassama L Chem Rev. 2025; 125(4):2120-2183.

PMID: 39818743 PMC: 11870016. DOI: 10.1021/acs.chemrev.4c00595.


Novel affibody molecules targeting the AXL extracellular structural domain for molecular imaging and targeted therapy of gastric cancer.

Zhang H, Zheng M, Cai Y, Kamara S, Chen J, Zhu S Gastric Cancer. 2024; 28(2):174-186.

PMID: 39644434 PMC: 11842530. DOI: 10.1007/s10120-024-01568-5.